<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Mexiletine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00379</strong>&#160; (APRD00242)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00379/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00379/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00379.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00379.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00379.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00379.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00379.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00379">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Mexiletina</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>Mexil&#233;tine</td><td>French</td><td>DCF</td></tr><tr><td>Mexiletinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Mexiletine Hydrochloride</strong>
          <div class="cas">5370-01-4</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000449/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000449/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: NFEIBWMZVIVJLQ-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 215.10769191</li>
              <li>Average Mass: 215.72</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000449">DBSALT000449</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cirumimeru</td><td>Tsuruhara Seiyaku</td></tr><tr><td>Mekiratin</td><td>Ohara Yakuhin</td></tr><tr><td>Melate</td><td>Medisa Shinyaku</td></tr><tr><td>Meldest</td><td>Taiyo Pharmaceutical</td></tr><tr><td>Meletin</td><td>Taiwan Biotech</td></tr><tr><td>Mequitolide</td><td>Towa Yakuhin</td></tr><tr><td>Metorekicin</td><td>Choseido Pharmaceutical</td></tr><tr><td>Mexicord</td><td>Polfa Grodzisk</td></tr><tr><td>Mexitil</td><td>Boehringer Ingelheim</td></tr><tr><td>Mexitilen</td><td>Boehringer Ingelheim</td></tr><tr><td>Minsetil</td><td>Zdravlje</td></tr><tr><td>Mobalen</td><td>Tatsumi Kagaku</td></tr><tr><td>Mugadine</td><td>Yung Shin</td></tr><tr><td>Novo-Mexiletine</td><td>Novopharm</td></tr><tr><td>Olzoron</td><td>Kobayashi Kako</td></tr><tr><td>Poeruten</td><td>Yoshindo</td></tr><tr><td>Ritalmex</td><td>Valeant</td></tr><tr><td>Teva-Mexiletine</td><td>Teva Neuroscience</td></tr><tr><td>Toi</td><td>Kyorin Rimedio</td></tr><tr><td>Tumetil</td><td>Boehringer Ingelheim</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/voltage-gated-sodium-channel-blockers">Voltage-Gated Sodium Channel Blockers</a></li></ul></td></tr><tr><th>CAS number</th><td>31828-71-4</td></tr><tr><th>Weight</th><td>Average: 179.2588<br>Monoisotopic: 179.131014171</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>17</sub>NO</td></tr><tr><th>InChI Key</th><td>VLPIATFUUWWMKC-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(2-aminopropoxy)-1,3-dimethylbenzene</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(N)COC1=C(C)C=CC=C1C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenol Ethers</td></tr><tr><th>Direct parent</th><td>Phenol Ethers</td></tr><tr><th>Alternative parents</th><td>Toluenes; Alkyl Aryl Ethers; Polyamines; Monoalkylamines</td></tr><tr><th>Substituents</th><td>alkyl aryl ether; toluene; polyamine; ether; amine; primary amine; primary aliphatic amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.</td></tr><tr><th>Pharmacodynamics</th><td>Mexiletine is a local anesthetic, antiarrhythmic agent (Class Ib), structurally similar to lidocaine, but orally active. Mexiletine has fast onset and offset kinetics, meaning that they have little or no effect at slower heart rates, and more effects at faster heart rates. It shortens the action potential duration, reduces refractoriness, and decreases Vmax in partially depolarized cells with fast response action potentials. Mexiletine either does not change the action potential duration, or decreases the action potential duration.</td></tr><tr><th>Mechanism of action</th><td>Mexiletine, like lidocaine, inhibits the inward sodium current required for the initiation and conduction of impulses, thus reducing the rate of rise of the action potential, Phase 0. It achieves this reduced sodium current by inhibiting sodium channels. Mexiletine decreases the effective refractory period (ERP) in Purkinje fibers in the heart. The decrease in ERP is of lesser magnitude than the decrease in action potential duration (APD), which results in an increase in the ERP/APD ratio. It does not significantly affect resting membrane potential or sinus node automaticity, left ventricular function, systolic arterial blood pressure, atrioventricular (AV) conduction velocity, or QRS or QT intervals</td></tr><tr><th>Absorption</th><td>Well absorbed (bioavailability 90%) from the gastrointenstinal tract.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>5 to 7 L/lg</li>
</ul></td></tr><tr><th>Protein binding</th><td>50-60%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic (85%) via CYP2D6 and CYP1A2 (primarily CYP2D6).</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Mexiletine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00259">2-hydroxymexiletine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/260">Details</a></td></tr><tr><td>Mexiletine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00260">p-hydroxymexiletine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/261">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Approximately 10% is excreted unchanged by the kidney. The urinary excretion of N-methylmexiletine in man is less than 0.5%.</td></tr><tr><th>Half life</th><td>10-12 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse, and coma.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Mexiletine Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7357</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6711</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8781</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9484</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7849</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8191</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5463</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.941</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9132</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6004</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6357
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7796
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9261
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6338 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8982
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6563
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Boehringer ingelheim</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Warrick Pharmaceuticals Corp.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Mexiletine increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion. </td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Mexiletine increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The hydantoin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Mexiletine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor mexiletine therapy for reduced effectiveness.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Fluvoxamine may increase the therapeutic and adverse effects of mexiletine.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The hydantoin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Mexiletine increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The hydantoin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Propafenone may increase the effect and toxicity of mexilitine.</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Mexiletine increases levels/toxicity of ramelteon</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of mexiletine</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Mexiletine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Mexiletine is initiated, discontinued or if the dose is changed.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Mexiletine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mexiletine if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Mexiletine increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>The strong CYP1A2 inhibitor, Mexiletine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Mexiletine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Mexilitene may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.</td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>Monitor for increased serum concentrations/toxic effects of mexiletine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased concentrations/effects if an SSRI is discontinued/dose decreased. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>